Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: HIV Infections
Interventions: HE2000; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Palm Springs, California • Palo Alto, California • San Francisco, California + 3 more

Conditions: Breast Cancer
Interventions: Trastuzumab, Bevacizumab, Docetaxel; Drug
Lead sponsor: Bhuvaneswari Ramaswamy; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tremelimumab; Biological · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Infarction, Brain Ischemia
Interventions: t DC stimulation, tDCStimulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 19 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions: A2B530, xT-Onco with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Inhalational Anthrax
Interventions: ETI-204, Placebo; Biological · Other
Lead sponsor: Elusys Therapeutics; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more

Conditions: Asthma, Obesity
Interventions: CXA-10, Matching Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Parkinson's Disease
Interventions: ABBV-0805, Placebo ABBV-0805; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more

Conditions: Weight Management
Interventions: one-hour dietary self-monitoring tool education session; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cholera
Interventions: Vaxchora; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Low dose, Intermediate dose, High dose, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Breast Cancer
Interventions: multiple beams utilizing either intensity-modulated or 3D-conformal techniques; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Personal Satisfaction
Interventions: Hyaluronic acid filler injection; Procedure
Lead sponsor: Marmur Medical; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions: Temozolomide, Stereotactic Radiosurgery (SRS); Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hyperinsulinism
Interventions: Sirolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Concussion, Brain
Interventions: Not listed
Lead sponsor: ElMindA Ltd; Industry
Eligibility: 12 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brighton, Michigan

Conditions: HIV
Interventions: Monetary Incentive, Questionnaire Timing, HIV Test Offering; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 64 Years
Enrollment: 8,572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions: Transcranial alternating current stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Participants Study
Interventions: N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg); Drug
Lead sponsor: Jon Dean; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetic Neuropathy
Interventions: Vegan diet and vitamin B12 supplement, Vitamin B12 supplement; Other · Dietary Supplement
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Education Session to Improve Program Adherence

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Hyaluronic Acid Filler for Dorsal Finger Volume Loss

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Sirolimus for the Treatment of Hyperinsulinism

Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment, Young Adults and Adults

HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)